NASHVILLE, Tenn.--(BUSINESS WIRE)--NuSirt Biopharma, Inc., is initiating a clinical trial with a goal of demonstrating whether the company’s patented technology may enhance the ability of a common Type 2 diabetes medication, metformin, to control blood sugar. The primary design of this Phase 2A trial is to test whether the combination of NuSirt technology and three different low doses of metformin can effectively control glucose levels when compared with full doses of metformin alone. In this trial, NuSirt’s technology employs a patented blend of leucine, an essential amino acid, coupled with an existing pharmaceutical compound.
Hey, check out all the research scientist jobs. Post your resume today!
